The Board of Directors of Strides Pharma Science Ltd (STAR) at its meeting held on 27 May 2021, has declared Final Dividend of Rs 2.5 per equity share. The Board Meeting commenced at 11:45 hrs and concluded at 13:15 hrs.
Strides Pharma Science Ltd Quarterly Result
The company has reported a consolidated net profit of Rs 43.74 crore in the fourth quarter of FY20. The company had posted a consolidated net loss of Rs 206.57 crore in the corresponding quarter a year ago. Revenue from operations in the fourth quarter stood at Rs 908.49 crore which was at Rs 618.64 crore in the year-ago period.
Similar Posts
- Cummins India Ltd Declares Final Dividend of Rs 8
- Havells India Limited Declares Final Dividend of Rs 3.5
Strides Pharma Science Ltd Dividend Record Date
The company in its letter has informed the exchanges that it has fixed (…) as the Record date. In addition, the declared dividend will be paid within 30 days.
Moreover, to receive dividend, you must have shares in your demat account on record date. Hence, you should buy shares before ex-dividend date. Note – If you buy shares on ex-dividend date, you will not be eligible to receive dividend. Bookmark our website for latest and upcoming dividend announced by companies in 2021.
Above all, here is the copy of statement, the company has sent to the exchanges:
This is to inform you that the Board of Directors at their meeting held today i.e., on May 27, 2021, have recommended final dividend of Rs. 2.50 /- per equity share of Rs. 10/- each for the financial year ended March 31, 2021. The dividend will be paid within 30 days from the date of shareholder’s approval at the ensuing Annual General Meeting of the Company.
Important Dates
- Company – Strides Pharma Science Ltd
- Script Name – STAR (NSE) and 532531 (BSE)
- Dividend Amount – 2.5 Rs Per Share
- Dividend Type – Final
- Ex-Dividend Date – NA
- Record Date – NA
- Payment Date – Within 30 Days.
Also, you can find more information about Strides Pharma Science Ltd on National Stock Exchange and Moneycontrol – Strides is engaged in the development, manufacture, and marketing of pharmaceutical products for regulated and emerging markets.
